| INTRODUCTION
In 2015, the US Food and Drug Administration (FDA) approved 2 novel lipid-lowering drugs, the proprotein convertase subtilisin/ kexin type 9 inhibitors (PCSK9 mab) alirocumab and evolocumab. 1, 2 Treatment indications were clear: for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) requiring further reduction in lowdensity lipoprotein cholesterol (LDL-C). Evolocumab was given the additional indication for homozygous familial hypercholesterolemia (HoFH). Understanding that "time is plaque" 3 and that PCSK9 mab offered heretofore unobserved intensive and predictable lowering of LDL-C incremental to statin therapy, many clinicians in the lipid and ASCVD prevention and treatment arenas prescribed these medicines according to the label. Nearly ubiquitous denials for these medications were rapidly encountered. In 2016, a Symphony study demonstrated approximately 80% initial denial rates, with final approvals between 25% and 50% for commercial and Medicare patients respectively. 4 An FH Foundation survey of impacted individuals assessed patient access to lipid-lowering therapies for FH. 5 Data from 163 participants revealed a 26% overall denial rate of medication coverage; 79% were denials of PCSK9 mab prescriptions, with 36% of these prescriptions being written for secondary preven- town hall meetings were well attended, demonstrating substantial appreciation and concern among clinicians regarding our inability to access PCSK9 mab for our patients.
This review documents the development of a novel and highly promising drug class, and the barriers to access encountered by clinicians and their patients across the United States. Pragmatic, meaningful, and implementable solutions are proposed to improve the PCSK9 mab access process for patients meeting the prescribing criteria specified by the FDA. Five well-considered definitions for each of the 5 specifications required to meet the PCSK9 mab's package inserts (PIs), as well as sample uniform prior authorization (PA) and appeals letters are presented. It is important to recognize that recent systematic denials for novel medications are not limited to PCSK9 mab; they affect other medicines today, and might impact future innovative therapies as well. Thus, resolving this matter is of paramount importance to preserve innovation and safeguard patient access to prescribed novel therapies, a foundation of the patientclinician relationship.
A brief discussion of pharmacoeconomics is necessary. Price is always the "elephant in the room" and therefore must at least be openly discussed. The list price -not the true negotiated price-for both PCSK9 mab is approximately $14,000 per year. 6 A number of articles, such as that by Kazi et al, 6 have evaluated the cost effectiveness of these medications using questionable criteria such as quality-adjusted life years (QALYs), a metric abandoned by the Affordable Care Act 7 as well as Europe because of its acknowledged inaccuracies. 8 In addition, a number of assumptions made in relevant pharmacoeconomics analyses proved incorrect, including an overestimation of the number of FH patients purportedly requiring a PCSK9 mab and an inaccurate forecast by the Institute for Clinical and Economic Review (ICER) that the drugs would cost the United States $1.2 billion in the first year after approval, whereas the actual expenditure was $83 million, just 1.2% of predicted. 9 Such prognostications likely precipitated a high level of caution among payers, causing frequent denials and a challenging appeal process.
Integrally involved in drug pricing, yet often overlooked, are
PBMs. Several PBMs control the majority of US prescriptions, negotiating deals between pharmaceutical companies and the end payers. 10 Like the payers, PBMs could clearly benefit from the findings and solutions detailed in this article.
| THE HISTORY AND IMPORTANCE OF PCSK9
Multiple levels of evidence support the causal role of LDL-C in the development of atherosclerosis. Most importantly, LDL-C reduction has been shown in numerous randomized controlled trials (RCTs) to reduce the risk of heart attack, stroke, and death. 17 The overexpression of PCSK9 was found to correlate with increased serum LDL-C. 18 Consistent with this observation, mutations in PCSK9 that cause FH are a gain of function. Following these discoveries, investigators identified loss of function mutations in PCSK9, which correlated with low serum levels of LDL-C and concomitant reduced risk for acute cardiovascular events. 19 In considerable subsequent investigation, PCSK9 emerged as a critical regulator of LDLR expression, and great effort has therefore been made to exploit this molecule for therapeutic purposes.
PCSK9 is produced as a zymogen (proPCSK9) by hepatocytes, and undergoes autocatalytic cleavage so as to facilitate its secretion and proper folding. 20 In the extracellular milieu, mature PCSK9 has no proteolytic activity; its active site is blocked by its previously cleaved prosegment. 21 Therefore, it serves simply as a binding protein. On hepatocytes, PCSK9 binds to a complex comprising the LDLR and an LDL particle. This binding occurs between PCSK9 22 and the epidermal growth factor-like repeat A domain of the LDLR. 23 This polymolecular assembly is incorporated into clathrincoated endosomal vesicles that are brought into the cytosol. 24 Within the cytosol, PCSK9 chaperones the LDLR complex into the lysosome for hydrolytic destruction, thereby reducing the recycling of LDLR to the hepatocyte cell surface and reducing LDL particle clearance capacity. When PCSK9 is not bound to the LDLR-LDL complex, lysosomal enzymes catabolize the LDL particle, but the LDLR is recycled back to the hepatocyte cell surface to initiate further LDL particle binding, uptake, and degradation. LDLR recycling can occur up to 150 times. 25 This model neatly explains why gain-of-function and loss-of-function PCSK9 mutations would be etiologic for elevations and reductions in serum levels of LDL-C, respectively. PCSK9 also regulates the expression of other lipoprotein cell surface receptors, including the LDL receptor related protein-1, 26 the very low-density lipoprotein receptor, and the apolipoprotein E receptor 2. 27 The clinical significance of these latter
interactions is yet to be established.
Alirocumab and evolocumab are safe and highly efficacious, and provide substantial incremental LDL-C reductions of between 55%
and 60% when used at their maximal FDA-approved doses. 28, 29 These therapies constitute an important and vital breakthrough in the management of patients who cannot achieve guideline-established levels of LDL-C reduction even with high-intensity statin therapy 
| DEFINITIONS FOR PI
The FDA has determined that alirocumab and evolocumab are indi- The following definitions, with their respective explanations, are
proposed to clarify these FDA-approved indications. Typically, at least 2 statins must be tried. 33 Although not studied in RCTs, when the lowest dose of multiple statins cannot be tolerated on a daily basis, alternative-dosing strategies can be considered.
| Maximally tolerated statin therapy
Under such circumstances, many experts advocate using statins with long half-lives administered 3 times per week, every other day, or even once per week. 
| Recommended definition 1
Maximally tolerated statin therapy is defined as the highest tolerated intensity and frequency of a statin, even if the dose is zero. This is preferably the guideline-recommended intensity of statin, but may of necessity be a lower intensity dose or reduced frequency of statin dosing, or even no statin at all. Statin intolerance can be defined as unacceptable adverse effects that resolve with discontinuation of therapy and recur with rechallenge of 2 to 3 statins, preferably ones that use different metabolic pathways, with 1 of which being prescribed at the lowest approved dose.
33,36
| HeFH and HoFH
FH is a common life-threatening genetic disorder characterized by substantially elevated LDL-C starting before birth. 37, 38 The life-long exposure to elevated LDL-C significantly augments the risk for ASCVD; those with FH have a 2.5-to 10-fold increased risk for ASCVD compared to control populations. 39 Importantly, early detection and treatment of these patients has been shown to improve outcomes. 39, 40 Most commonly caused by mutations in the LDLR, apoB, or the PCSK9 genes, FH is inherited in an autosomal dominant pattern. 41, 42 Appropriate utilization of these ICD-10 codes will foster enhanced FH classification, identification, and much-needed family-based cascade screening.
| Recommended definition 2
"HeFH is defined as untreated LDL-C ≥160 mg/dL for children and ≥190 mg/dL for adults and with 1 first-degree relative similarly affected or with premature coronary artery disease or with positive genetic testing for an LDL-C-raising gene defect (LDLR, apoB, or PCSK9)." 
| Recommended definition 3
"HoFH is defined as LDL-C ≥400 mg/dL and ≥1 parent with clinically diagnosed FH, positive genetic testing for 2 LDL-C-raising gene defects (LDLR, apoB, or PCSK9), or autosomal-recessive FH." (Tables 3 and 4) . 34, 35 The most recent AACE Guidelines introduced a new level of extreme risk, with an associated concomitant recommended LDL-C goal of <55 mg/dL (Table 4) . 
|

| Prior authorization
The PA has become a nearly universal tool to limit patient access to medications. PAs require that healthcare practitioners collect specific data deemed necessary for medication approval. Complex paperwork (up to 17 pages in the case of the PCSK9 mab) often delays or discourages patient access to newer or more costly drugs. Justification of the PA process by payers includes the assertion that this process is necessary to avoid potential overuse of medications. 10 Prior to the 20 All of these RCTs demonstrated a reduction in major cardiovascular events. Italic type indicates statins and doses that have been approved by the FDA but were not tested in the RCTs reviewed.
1 Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice. There might be a biological basis for a lessthan-average response. and, assuming all definitions are met, it is recommended that patients who meet these requirements be granted access to therapy. ≥2 other major ASCVD risk factors <100 ≥100
Evidence of end-organ damage
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
For patients with ASCVD or diabetes mellitus, consideration should be given to use of moderate or high-intensity statin therapy, irrespective of baseline atherogenic cholesterol levels.
1 For those at moderate risk, additional testing may be considered for some patients to assist with decisions about risk stratification.
2 For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C <70 mg/dL) is considered a therapeutic option. , risk calculators should not be used because they may underestimate risk. Stage 5 CKD (or on hemodialysis) is a very high-risk condition, but results from randomized controlled trials of lipidaltering therapies have not provided convincing evidence of reduced ASCVD events in such patients. Therefore, no treatment goals for lipid therapy have been designed for stage 5 CKD. 4 If LDL-C is ≥190 md/dL, consider severe hypercholesterolemia phenotype, which includes familial hypercholesterolemia. Lifestyle intervention and pharmacotherapy are recommended for adults with the severe hypercholesterolemia phenotype. If it is not possible to attain desirable levels of atherogenic cholesterol, a reduction of at least 50% is recommended. For familial hypercholesterolemia patients with multiple or poorly controlled other major ASCVD risk factors, clinicians may consider attaining even lower levels of atherogenic cholesterol. Risk calculators should not be used such patients.
5 High-risk threshold is defined as ≥10% using the Adult Treatment Panel III Framingham Risk Score for hard CDH (myocardial infarction or CHD death), ≥15% using the 2013 Pooled Cohort Equations for hard ASCVD (myocardial infarction, stroke, or death from CHD or stroke), or ≥45% using the Framingham long-term (to age 80 years) CVD (myocardial infarction, CHD death, or stroke) risk calculation. Clinicians may prefer to use the other risk calculators, but should be aware that quantitative risk calculators vary in the clinical outcomes predicted (eg, CHD events, ASVCD events, cardiovascular mortality), the risk factors included in their calculation, and the timeframe for their prediction (eg, 5 years, 10 years, or long term or lifetime). Such calculators may omit certain risk indicators that can be very important in individual patients, provide only an approximate risk estimate, and require clinical judgment for interpretation.
| STEP therapy
Step therapy has been defined as "a prior authorization program that encourages the use of less costly yet effective medications before more costly medications are approved for coverage." 55 It has been designed, however, to lower prescription drug costs. Ostensibly, it also provides practitioners with optimal pathways to utilize different classes of drugs when treating particular conditions. Frequently though, it prioritizes the utilization of generic medications (assumed to be less costly) over branded medications.
Step therapy is ubiquitous in medical practice. Typically, medications are divided into tiers, beginning with the least costly prescriptions. Clinicians are required to begin with the first tier; they cannot progress to the second and third tiers until they have documented proof that their patients have failed long trials with lower-tier medications. Criteria for moving from a lower to a higher tier can be therapeutic failure, medication intolerance, or inability to treat a condition appropriately. Thus, step therapy has been aptly dubbed "fail first" therapy.
Step 1 medications are generally generic products and do not require prior authorization.
Step 2 medications are often branded drugs that are preferred by a particular payer, insurer, or heath care system.
Step 3 medications are brands that are not preferred and typically require extensive and burdensome PAs and involve substantially greater costs to patients.
Step therapy's requirement for a patient to try and fail a less costly medication prior to being prescribed what might actually be the optimal drug for that particular patient undermines the essence of medical practice from both a personalized and population perspective. Though this custom can reduce short-term prescription costs, it may have a negative impact on long-term patient outcomes. In fact, savings attributed to lower formulary costs may actually be due to health-averse effects such as nonadherence and diminished access to medicines. 56 In a review published in 2014 by Rahul K. Nayak and Steven D. Pearson, CEO of ICER, step therapy is acknowledged to have the "potential to create conflict between the goals of cost control and the ability to tailor care to the perceived needs of the individual patient." 57 In an article on the ethics of a fail first policy, the authors outline guidelines that should be followed to ensure that patients are protected and receive timely and appropriate access to needed medications. 57 They admonish that cost saving should be weighed against long-term outcomes. First step drugs should also be clinically appropriate, and failure should never lead to clinical harm.
Opting out on clinical grounds should be quick and easy, they caution, and failure should be clearly defined. Finally, it is emphasized
that "rationale and rules should be explicit and transparent." Evidently, many payers have not embraced these recommendations.
Consequently, patients commonly experience unnecessary delays in acquiring the medications their clinicians have prescribed. Often they are denied. With regard to the PCSK9 mab, such delays in drug access may be life threatening.
Patients with ASCVD and FH are at particularly high risk for future cardiovascular events. 29 All cholesterol guidelines emphasize the importance of aggressive statin therapy in such patients. Failure to achieve adequate LDL-C reduction and intolerance to medications are indications to utilize nonstatin therapies. As time is plaque in high-risk patients, they need access to nonstatin therapy quickly and hindrance free. This typically does not occur; instead, patients usually suffer long wait times before receiving their prescribed medicines.
Often, they never obtain them. Examining this issue, Nayak and Pearson reviewed several scenarios based on level of ethical burden to justify step therapy. 57 They specifically pointed to statin therapy (at a time when many of the statins were still branded and therefore costly) as requiring a high ethical burden to justify step therapy. With PCSK9 mab now available and indicated for patients with clinical ASCVD and/or FH, this same standard should apply. Patients who require additional LDL-C lowering, despite maximally tolerated statin therapy, should be treated swiftly and aggressively as uniformly recommended by current professional society cholesterol guidelines.
Step therapy should not be a barrier.
Finally, it is important to note that formulary construction itself has been used for cost containment. 58 Restricting access to more expensive medications, including branded products or novel therapies, has the immediate impact of reducing cost. Looking at the longterm, however, we again witness something concerning. Coverage gaps (through formulary restrictions) can lead to worse patient outcomes. 59, 60 Clearly, plan exclusions that deny patients entire classes of medications, such as the PCSK9 mab, should be eschewed.
| Appeals
The appeals process enables clinicians to petition for a change in an insurance provider's decision regarding a prescribed therapeutic. In the case of PCSK9 mab, appeals are the norm rather than the exception. As noted above, the Symphony report 5 found that greater than 80% of initial prescriptions for PCSK9 mab are denied. Of these initial denials, after extensive appeals, 46.6% of Medicare and 26.7% of privately insured patients ultimately gained approval. suggesting a flawed initial review process. Finally, when federal oversight is involved (eg, Medicare), initial and final approval rates are significantly higher. Thus, the processes of approval/denial for the PCSK9 mab as well as the impact of these high denial rates on patients' outcomes need to be explored. 61 Clinicians must frequently intervene with insurance providers, advocating on behalf of patients, but unfortunately eroding valuable time and energy. There is also an unrecognized potential economic risk some physicians must bear. Blue Cross Blue Shield of North Carolina, for example, specifies on its website 62 that when the value of a dispute exceeds $1000, physicians must personally pay a $250 dollar filing fee to initiate any second appeal. This establishes a clear conflict of interest; the doctor must pay the insurance provider to obtain a valid prescription that has already been written. Given the high denial rate for the PCSK9 mab, such a requirement clearly represents an untenable financial barrier for physicians.
Accompanying this article is a appeals template letter providing guidance to clinicians and payers to improve appeal success and patient access to prescribed therapy (see Supporting Information, Appendix 2, in the online version of this article).
| CONCLUSION
Unnecessary PCSK9 mab access barriers have been identified, and cogent solutions have been recommended. It is only with clear guidance to all invested parties, including patients, clinicians, payers, and
PBMs, that appropriate access to PCSK9 mab will be achieved. As 
